KYGEVVI™ (doxecitine and doxribtimine) powder for oral solution 2 g/2 g is now FDA approved for the treatment of thymidine kinase 2 deficiency (TK2d) in adult and pediatric patients with an age of symptom onset on or before 12 years.
RHEUMATOLOGY
The Women's Health Fellowship Program application is now closed. Learn More
For US Healthcare Professionals Only
